Welcome to our dedicated page for Biocorrx SEC filings (Ticker: BICX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
a company that changes lives biocorrx® is a leading edge healthcare solutions company focused on improving the lives of those struggling with alcohol and opioid addiction. designed to treat alcoholism and certain opioid addictions, the biocorrx® recovery program is used by a network of independently owned and operated treatment centers located throughout the united states. the program consists of a proprietary long-lasting implant of the fda approved medication, naltrexone, which is proven to substantially reduce cravings for drugs and alcohol. it's a high-quality, comprehensive and cost- effective recovery program built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering addicts.BioCorRx (BICX) filed its Q3 2025 10‑Q, highlighting its first meaningful product revenue following the Lucemyra asset purchase. Supply and distribution sales reached $635,224 for the quarter and $946,572 year‑to‑date, driving total net sales of $948,362 for the nine months. The company recorded a Q3 net loss attributable to BioCorRx of $1,917,873 and a year‑to‑date loss of $3,992,701, reflecting higher operating expenses as the business scales.
Cash was $287,688 with a working capital deficit of $13,575,951, and management disclosed substantial doubt about the company’s ability to continue as a going concern. Total assets rose to $7,533,473, including intangible assets of $3,011,833 and goodwill of $2,840,400 tied to the US WorldMeds Lucemyra acquisition, while total liabilities were $20,297,768. The company recognized Q3 grant income of $867,130 under NIDA awards and reported a grant receivable of $761,515 and deferred grant revenue of $56,590. Operating expenses increased to $2,580,811 in Q3, including research and development of $1,004,660 and SG&A of $1,145,353, leading to a Q3 operating loss of $1,945,587.